Stockholm Ischemic Heart Disease Study: Difference between revisions
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}}; {{AE}} {{Rim}} ==Overview== Stockholm Ischemic Heart Disease study is a randomized open label trial that assessed the effect ..." |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Stockholm Ischemic Heart Disease study is a randomized open label trial that assessed the effect of clofibrate and nicotinic acid vs placebo on ischemic heart disease mortality. | The Stockholm Ischemic Heart Disease study is a randomized open label trial that assessed the effect of [[clofibrate]] and [[nicotinic acid]] vs placebo on ischemic heart disease mortality. | ||
==Study Description== | ==Study Description== | ||
| Line 17: | Line 17: | ||
| '''Allocation'''||Randomized | | '''Allocation'''||Randomized | ||
|- | |- | ||
| '''Endpoint'''||Ischemic heart disease | | '''Endpoint'''||Ischemic heart disease mortality | ||
|- | |- | ||
| '''Masking'''||Open label | | '''Masking'''||Open label | ||
| Line 34: | Line 34: | ||
==Publications== | ==Publications== | ||
The Stockholm Ischemic Heart Disease study revealed a 36% decrease in ischemic heart disease mortality among patients ho recieved the treatment vs control, an effect most likely related to the [[triglyceride]]s plasma concentration particularly among patients with a triglyceride level higher than 1.5 mmol/l and those who had a decrease in the serum triglyceride by at least 30%. | |||
==References== | ==References== | ||
Revision as of 02:55, 19 August 2014
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
Stockholm Ischemic Heart Disease Study On the Web |
|
American Roentgen Ray Society Images of Stockholm Ischemic Heart Disease Study |
|
Risk calculators and risk factors for Stockholm Ischemic Heart Disease Study |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
The Stockholm Ischemic Heart Disease study is a randomized open label trial that assessed the effect of clofibrate and nicotinic acid vs placebo on ischemic heart disease mortality.
Study Description
| Study Description | |
| Study Design | |
| Allocation | Randomized |
| Endpoint | Ischemic heart disease mortality |
| Masking | Open label |
| Study Details | |
| Primary Purpose | |
| Condition | Survivors of a myocardial infarction |
| Study Arms | Clofibrate and nicotinic acid Control |
| Population Size | 555 subjects |
Publications
The Stockholm Ischemic Heart Disease study revealed a 36% decrease in ischemic heart disease mortality among patients ho recieved the treatment vs control, an effect most likely related to the triglycerides plasma concentration particularly among patients with a triglyceride level higher than 1.5 mmol/l and those who had a decrease in the serum triglyceride by at least 30%.